Star Therapeutics is a biopharmaceutical company focused on developing life-changing therapies for rare diseases. They aim to address the unmet need for treatments for the millions of patients suffering from rare conditions. Their portfolio includes first-in-class antibody therapeutics built on novel biology.

Star Therapeutics

Star Therapeutics is a biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible for the millions of patients in urgent need. Our innovation engine starts with identifying multiple rare diseases that share a common biology and then discovering novel therapeutics that can treat these diseases with a single therapy. Star consists of a family of companies, each focusing on a specific area of novel biology and developing first-in-class antibody therapeutics. Electra Therapeutics, the first company within our portfolio to be unveiled, is developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. 

Westlake Village BioPartners

Cormorant Asset Management

Cowen Healthcare Investments

New Leaf Venture Partners

OrbiMed

RA Capital Management

Redmile Group

Our CEO, Adam Rosenthal, shares the origin story and mission of Star Therapeutics. We look at the “the long tail of disease”, the thousands of rare diseases with inadequate treatment, and see limitless opportunities to make an impact.
#UniverseOfPossbilities

Star is applying expertise in rare diseases and antibody drug discovery to advance drug programs that target multiple diseases with a single therapy.
#UniverseOfPossibilities

Star Therapeutics emerges from stealth mode raising $100M in financing since inception to be an innovation engine for rare disease therapies.
#UniverseOfPossbilities

Introducing Star Therapeutics. Our sights are set on developing life-changing therapies for as many rare diseases as possible for the millions of patients globally.
#UniverseOfPossibilities

Metric
Company Name	Star Therapeutics
Symbol
MSH ID	COM:STAR-THERAPEUTICS
Market	PRIVATE
Sector	Healthcare
Industry	Biopharmaceuticals
Country	US
Stage
Employee Count	11
Website	star-therapeutics.com
LinkedIn	star-tx
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	53.88
28-Day Growth Score	20.72
90-Day Growth Score	59.39
365-Day Growth Score	80.55

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:STAR-THERAPEUTICS

Star Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue